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http:WHAT THIS PAPER ADDS
In patients with intermittent claudication, endovascular treatment of above-the-knee arterial lesions should
preferably be performed using balloon angioplasty. When balloon angioplasty does not result in less than 30%
residual stenosis, or a ﬂow limiting dissection occurs, bailout stenting may be performed. Scientiﬁc evidence for
using drug-eluting stents is inconclusive, and, as it is unknown if they perform better, it is recommended to use
the less expensive bare stents. For patients with critical limb ischemia and only above-the-knee lesions, no
substantial evidence is available to recommend a speciﬁc endovascular treatment strategy.Objective: To evaluate 1 to 36 month follow-up outcomes of different endovascular treatment strategies in
above-the-knee (ATK) arterial segments in patients with intermittent claudication (IC) and critical limb ischemia
(CLI).
Methods: Studies indexed in Medline and Embase from 1980 to November 2013 of randomized controlled trials
comparing balloon angioplasty (PTA) or drug-eluting balloon (DEB) with optional bailout stenting, or primary
stenting using a bare stent (BS) or drug-eluting stent (DES) to one another were included. Methodological quality
of each trial was assessed using the Cochrane Collaboration tool, and quality of evidence was assessed using the
GRADE system. Outcomes assessed were quality of life, walking capacity evaluated by treadmill or questionnaire,
change in Rutherford classiﬁcation, target lesion revascularization (TLR), bypass, binary restenosis, late lumen
loss, stenosis grade, amputation, death, major adverse cardiac events, or event-free survival with follow-up
periods of at least 1 month.
Results: Twenty-three trials including 3314 patients in total were identiﬁed. Eighty-ﬁve per cent patients had IC
and 15% CLI. Fifteen trials showed no systematic beneﬁt of BS over PTA. One trial comparing DES and PTA
reported no signiﬁcant differences in walking capacity or Rutherford classiﬁcation. Four trials showed a beneﬁcial
effect on TLR rate, but not on Rutherford classiﬁcation of DEB compared with PTA. In four trials DES did not
systematically perform better than BS.
Conclusion: In general, performing PTA with optional bailout stenting for ATK lesions is the preferred strategy in
patients with IC. For CLI, more studies are needed for recommending an optimal treatment strategy.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Single or multiple chronic stenoses or occlusions in the
lower limb arteries can result in intermittent claudication
(IC) or critical limb ischemia (CLI). Patients with IC have
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//dx.doi.org/10.1016/j.ejvs.2014.02.011which reduces their quality of life.1 Patients with CLI pre-
sent with ischemic rest pain or ischemic tissue loss with
limited or even absent healing. If not treated adequately or
when treatment is unsuccessful, amputation in these pa-
tients may be inevitable.1
The aims of treatment for IC or CLI are very different. For
patients with IC, the goal is to restore walking capacity, and
improve quality of life. For CLI, the objective is to prevent
amputation by establishing wound healing, and to relieve
ischemic rest pain. To achieve this, immediate restoration of
blood ﬂow is essential. Revascularization can be performed
surgically or endovascularly, but endovascular treatment is
preferred because it is less invasive than open surgery.1 For
IC, invasive treatment is only indicated when supervised
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 5 p. 524e535 May/2014 525exercise or medical therapy fails to relieve symptoms, and
the decline in walking capacity is invalidating.1
For patients with above the knee (ATK) lesions the Trans-
Atlantic Inter-Society Consensus II (TASC II)1 currently rec-
ommends performing balloon angioplasty (PTA) with
optional bailout stenting. However, over the past decade
several other endovascular revascularization strategies have
been proposed, such as drug-eluting balloon (DEB) angio-
plasty with optional bailout stenting, or primary stenting
using a bare stent (BS) or drug-eluting stent (DES). It is as
yet unclear if these innovations result in better treatment
outcomes that are clinically relevant.
The aim of our study was to determine the optimal
treatment strategy for patients with IC or CLI caused by
ATK arterial lesions. As randomized controlled trials
(RCTs) provide the best evidence on the relative effec-
tiveness of revascularization strategies by a direct com-
parison of clinically relevant outcomes, we performed a
systematic review of the 1 to 36 month follow-up out-
comes of RCTs comparing different endovascular treat-
ment strategies in ATK arterial segments in patients with
CLI and IC.MATERIALS AND METHODS
This review was conducted according to the Preferred
Reporting Items for Systematic Review and Meta-Analysis
(PRISMA).2 The protocol of this review was not published
or registered in advance.Eligibility criteria
Types of studies. RCTs.
Types of patients. Patients with IC or CLI treated for ATK
arterial stenosis or occlusion.
Types of intervention. Studies comparing (1) BS versus PTA,
(2) DES versus PTA, (3) DEB versus PTA, and (4) DES versus
BS.
Types of outcome measures. Quality of life, walking capacity
evaluated by treadmill or questionnaire, change in Ruth-
erford classiﬁcation, TLR, bypasses performed, binary
restenosis (or patency), late lumen loss, stenosis grade,
amputation, death, major adverse cardiac events (MACE),
and event-free survival (EFS) for follow-up periods of at
least 1 month. EFS is deﬁned as free from death, target
vessel revascularization, major or minor amputation, or
myocardial infarction.
Outcomes for the PTA strategy were only eligible when
bailout stenting was not considered as a failure in data
analysis.Information sources
Electronic databases, Medline (PubMed) and OVID Embase,
were searched from 1980 to the present. The last search
was performed on 5 November 2013. The literature search
was performed with the help of a clinical librarian. No limits
were applied.Search strategy
The search strategy for both Medline and Embase consisted
of three components: peripheral arterial disease, angio-
plasty/stent, and RCT. For these components several search
terms were formulated. These terms were combined using
‘OR’, and the three components were combined using
‘AND’. Completeness of the search was checked by verifying
whether previously assessed relevant articles were found. If
articles were missed, relevant search terms were added to
the search strategy.
A detailed search strategy is provided in Appendix 1
(online supplementary material).Study selection
Two authors (SJ and AC) independently assessed eligibility
by screening the titles and abstracts of the identiﬁed arti-
cles according to the eligibility criteria. After this initial se-
lection, both authors independently assessed the full texts
of the potential relevant articles for eligibility. After selec-
tion, discrepancies between the authors were resolved by
discussion and consensus was reached.Methodological quality and risk of bias in individual
studies
For assessing methodological quality the Cochrane Collabo-
ration’s tool for assessing risk of bias was used.3 This tool has
been speciﬁcally developed for assessing the risk of bias in
RCTs on seven items: selection bias considering (1)
adequateness of random sequence generation and (2) allo-
cation concealment, (3) performance bias considering
adequateness of blinding participants and personnel during
intervention, (4) detection bias considering adequateness of
blinding during outcome assessment, (5) attrition bias
considering completeness of outcome data, (6) reporting bias
considering adequateness of reporting outcomes, and (7)
other biases. All items were scored as adequate, unclear, or
inadequate, as deﬁned by the Cochrane Collaboration.
Additionally, the presence of baseline differences between
the intervention and the comparator strategies for several
risk factors (i.e. age, gender, smoking, diabetes mellitus, renal
failure, coronary artery disease, hyperlipidemia, hyperten-
sion, Fontaine or Rutherford stage, lesion calciﬁcation, ste-
nosis grade, number of occlusions, and lesion length) were
scored. Items were scored as ‘adequate’ when all relevant
risk factors were reported, and all did not differ signiﬁcantly
between strategies; ‘inadequate’ when one or more of the
relevant risk factors differed signiﬁcantly between strategies;
or ‘unclear’ when risk factors reported did not differed
signiﬁcantly, but not all relevant risk factors were reported.
When there were multiple publications on the same RCT, the
methodological quality was assessed only once.Data extraction
Data extraction was performed in a standardized manner
using a data extraction form. Two authors (SJ and AC)
independently extracted the data from the included articles.
526 S. Jens et al.Consensus was reached after independent data extraction.
Disagreements were resolved by discussion.
The following data were extracted: study design, that is
intervention and comparator characteristics, pre- and post-
interventional antiplatelet therapy; study population char-
acteristics, for example age, gender, and several risk factors
such as presence of diabetes mellitus and smoking status;
and outcomes reported, as deﬁned by the eligibility criteria.
For the outcomes quality of life, walking capacity evaluated
by treadmill or questionnaire, death, MACE, and EFS data
were extracted on a per-patient basis. Data on change in
Rutherford classiﬁcation, TLR, bypasses performed, binary
restenosis, late lumen loss, stenosis grade, and amputation
preferably were extracted on a per-limb/per-lesion basis.
For dichotomous data, extraction of data presented by
survival analysis, that is hazard ratio (HR, calculated using
Cox-regression analysis) with standard error (SE) or event
rate per strategy, and the p value (calculated by Cox-
regression analysis or the Log Rank test), were preferred.
If not reported, raw data of the number of events versus no
events were extracted.
For continuous data the mean or median scores with
standard deviation (SD) or range and total number of pa-
tients were extracted when possible. If not reported, the
mean difference with SE and p value (either calculated by
an independent t test, ManneWhitney test, or by ANCOVA)
were extracted. For outcomes with three or more cate-
gories, that is data from Rutherford change, data per
category and p value (calculated by c2 test) were extracted.
Authors were not contacted in case of missing data.Figure 1. Flow diagram of search and study selection. RCT, ran-
domized controlled trial.Summary estimates of outcomes
Overview of summary estimates. Multiple outcomes were of
interest for this review. The summary measure, therefore,
depended on the outcome assessed. For dichotomous
outcomes such as change in Rutherford classiﬁcation (when
dichotomized), TLR, bypasses performed, binary restenosis
(or patency), amputation, death, and MACE, the risk ratio
(RR) was the principle summary measure. For continuous
outcomes such as quality of life, walking capacity evaluated
by treadmill or questionnaire, late lumen loss, and stenosis
grade, the summary measure was the weighted mean dif-
ference (MD) between strategies.
Pooling of summary estimates. Data were pooled using the
random effects model. Heterogeneity was not tested sta-
tistically, but assumed a priori, because of differences in
population and lesion characteristics and the use of
different types of stents or balloons between studies.
Data were only pooled for the comparisons of BS versus
PTA, DES versus PTA, DEB versus PTA, and DES versus BS
when follow-up duration was similar between studies. For
pooling of dichotomous data the RR were calculated, and
for continuous data the weighted MD, with 95% conﬁdence
interval (95% CI) and p value. Data reported as median and
range were not converted to mean and SD, respectively,
and were therefore excluded from meta-analysis. Summary
estimates were calculated with Review Manager (RevMan,Version 5.2. The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, 2008). For dichotomous data
that had no p value readily available, the p value was
calculated using the Fisher’s exact test in GraphPad Prism
(Version 5.01, GraphPad Software, La Jolla, CA, USA, www.
graphpad.com). If p <.05, the RR with 95%CI was calcu-
lated using Review Manager.
Quality of evidence
For every outcome, the quality of evidence was assessed in
consensus by two authors (SJ and AC) according to the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system.4 This system divides the
quality of results into four categories: high (þþþþ),
moderate (þþþ), low (þþ), and very low (þ) quality. To
assess the quality for RCTs, the quality initially was graded
as high (þþþþ), but downgraded if risk of bias, inconsis-
tency of results, indirectness of evidence, imprecision, or
publication bias is present. For this review, because of the
inability to assess inconsistency and publication bias for
most outcomes, quality of evidence was downgraded to
moderate quality (þþþ) in advance for all outcomes.
Indirectness of evidence was graded as absent in advance,
as the eligibility criteria included only studies that evaluated
patients with IC or CLI. Therefore, quality of evidence was
only downgraded to low quality (þþ) when risk of bias or
imprecision was present, or to very low quality (þ) when
risk of bias and imprecision were present. Risk of bias was
deﬁned as present, when ﬁve or more items on the
Cochrane Collaboration’s tool were graded as unclear or
high risk of bias. Imprecision was deﬁned as present when
less than 100 patients were evaluated for an outcome.
When meta-analysis of an outcome could be performed,
quality of evidence was downgraded when the average risk
of bias of the relevant RCTs had ﬁve or more items with a
high risk of bias. When the pooled data had outcomes on
less than 100 patients, quality of evidence was downgraded.
Table 1. Study and patient characteristics.
Study Comparison Patients,
N
% FII/
FIII/
FIV
or IC/CLI
Lesions,
N
Age (y),
mean
(SD)
or
median
(range)
Males,
N (%)
Smoking,
N (%)
Diabetes,
N (%)
Renal
failure,
N (%)
CAD,
N (%)
Stroke,
N (%)
Hyperlip.,
N (%)
Hypertens.,
N (%)
Occlusions,
N (%)
Stenosis,
%
(mean/
SD)
Lesion
length
(mm),
mean
(SD)
Primary
outcome
Industry
sponsored
BS vs PTA
Brancaccio
20125
Nitinol-S 50 42/24/
34
50 73 (d) 23 (46) 20 (40) 20 (40) 7 (14) 7 (14) d 31 (62) 34 (68) d d d Embolic load No
Laird 2010/
20126,7
Nitinol-S 206 100/0/0 234 67 (10) 143
(69)
156 (76) 79 (38) d 114
(55)
d 162 (79) 180 (87) 41 (18) 74 (18) 68 (43) 1 y TLR Yes
Dick 20098 Nitinol-S 73 95/1/4 73 69 (10) 50 (68) 29 (40) 22 (30) d 24 (33) 4 (5) 67 (92) 60 (82) 28 (38) 90 (16) 73 (57) 6 mo
restenosis
No
Saxon 2003/
20089,10
PTFE-Nitinol-
S
197 FIIeFIV 197 67 (10) 150
(76)
96 (49) 70 (36) 16 (8) 94 (48) 17 (9) 117 (59) 133 (68) 49 (25) 70 (40) 70 (40) 1 y primary
patency with
ABI change
<.15
Yes
Sabeti
200713/
Schillinger
200711/
Schillinger
200612
Nitinol-S 104 87/3/10 104 67 (10) 55 (53) 46 (44) 39 (38) d 74 (71) 7 (7) 93 (89) 95 (91) 36 (35) 90 (10) 96 (70) 6 mo binary
restenosis
No
Krankenberg
200714
Nitinol-S 244 FIeFIV
(2 pts
FI)
244 66 (10) 168
(69)
172 (70) 81 (33) 25 (10) 90 (37) 20 (8) 148 (61) 202 (83) 75 (31) 86 (7) 45 (28) 1 y binary
restenosis
Yes
Greenberg
200415
Nitinol-S 266 FIIeFIV 352 68 (10) 170/
260
(65)
208/257
(81)
98/260
(38)
d 85/256
(34)
d d d d d 34 (30) 30 day death,
periprocedural
MI and 9 mo
TLR
No
Chalmers
201316
Nitinol-S 150 82/18 150 68 (9) 123
(82)
38 (25) 52 (35) 17 (11) 58 (39) d d 100 (67) 140 (93) d 120 (53) 1 y binary
restenosis
Yes
Rastan
201317
Nitinol-S 246 79/21 246 Mean 73
(41e89)
158
(64)
57 (23) 91 (37) d 106
(43)
d 194 (79) 210 (85) 81 (33) d 42 (30) 1 y primary
patency
Yes
Grenacher
200418
Palmaz-S 116 pts
(124
limbs)
76/8/16 124 67 (10) 80
(65)a
59 (48)a 54 (44)a d d d 67 (54)a 61 (49)a 39 (31) 84 (14) 15 (12) 1 and 2 y
primary
patency
Not
reported
Grimm
200119
Palmaz-S 53 100/0/0 53 69 (9) d d d d d d d d 16 (30) 88 (13) 29 (20) Unclear Not
reported
Cejna 1999/
200120,21
Palmaz-S 141 pts
(154
limbs)
70/12/
18
186 Mean 67
(39e87)
95
(62)a
92 (60)a 63 (41)a d d d 69 (45)a 67 (44)a 60 (39) d 24 (2) 12 mo
primary
patency
Not
reported
Zdanowski
199922
Stent 32 15.5/
19/
65.5
32 Median
71
(41e86)
14 (44) 11 (34) 10 (31) d d d d 8 (25) 32 (100) 100 (0) 72 (20
e200)
Unclear Not
reported
Vroegindeweij
199723
Palmaz-S 51 100/0/0 51 Mean 64
(41e82)
36 (71) 32 (63) 6 (12) d 15 (29) d 16 (31) 9 (18) 9 (18) d d Unclear Not
reported
Continued
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Table 1-continued
Study Comparison Patients,
N
% FII/
FIII/
FIV
or IC/CLI
Lesions,
N
Age (y),
mean
(SD)
or
median
(range)
Males,
N (%)
Smoking,
N (%)
Diabetes,
N (%)
Renal
failure,
N (%)
CAD,
N (%)
Stroke,
N (%)
Hyperlip.,
N (%)
Hypertens.,
N (%)
Occlusions,
N (%)
Stenosis,
%
(mean/
SD)
Lesion
length
(mm),
mean
(SD)
Primary
outcome
Industry
sponsored
Becquemin
200324
Palmaz-S 227 79/6/15 227 66 (11) 142
(63)
148 (65) 27 (12) d 59 (26) 16 (7) 91 (40) 118 (52) 50 (22) d 25 (18) 1 y binary
restenosis
Yes
DES vs PTA
Dake 2011/
201325,26
PTX-ES 474 91.5/5/
3.5
498 68 (10) 307
(65)
404 (85) 216 (46) 49 (10) 91 (19) d 346 (73) 404 (85) 135 (27) 79 (17) 54 (40) 1 y EFS Yes
DEB vs PTA
Werk 200827 PTX-EB 87 94/6/0 87 69 (d) 52 (60) 36 (41) 41 (47) d d d 50 (57) 69 (79) 14 (16) 84 (14) 59 (8
e226)
6 mo LLL Yes
Tepe 200828 PTX-EB 102 FIIeFIV 102 68 (9) 65 (64) 23 (23) 49 (48) d d d 67 (66) 83 (81) 27 (26) 90 (7) 74 (65) 6 mo LLL Yes
Werk 201229 PTX-EB 91 96/2/2 107 71 (8) 56 (62) 49 (54) 32 (35) d 29 (32) 7 (8) 44 (48) 60 (66) 28 (31)
in
patients
77 (d) 68 (54) 6 mo LLL Yes
Fanelli 201230 PTX-EB e FIIeFIV 92 d d d d d d d d d 14 (15) 84 (4) d 6 mo LLL No
DES vs BS
Lammer
201331
Heparin-ES
vs nitinol-S
141 FIIeFIV 141 69 (9) 100
(71)
98 (70) 50 (35) 17 (12) 31 (22) d 96 (68) 118 (84) 102 (72) d 182 (65) 1 y primary
patency
Yes
Duda
(SIROCCO I)
2002/200632,34
Sirol-ES vs
nitinol-S
36 FIIeFIII 36 66 (d) 27 (75) 9 (25) d d 13 (36) d 21 (58) 25 (69) 21 (58) 88 (17) 86 (d) 6 mo
stenosis
Yes
Duda
(SIROCCO II)
2005/200633,34
Sirol-ES vs
nitinol-S
57 FIIeFIII 57 67 (10) 4 (70) 26 (46) 22 (39) d 28 (49) d 38 (67) 39 (68) 38 (67) 92 (12) 81 (41) 6 mo lumen
diameter
Yes
Dake 2011/
201325,26
PTX-ES vs
BMS
120 FIIeFIV 125 d d d d d d d d d d d d d Yes
ABI ¼ ankle-brachial index; BMS ¼ bare metal stent; BS ¼ bare stent; CAD ¼ coronary artery disease; DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent; EB ¼ eluting balloon;
EFS ¼ event-free survival; ES ¼ eluting stent; FII/FIII/FIV ¼ Fontaine stage II, III, or IV; LLL ¼ late lumen loss; MI ¼ myocardial infarction; mo ¼ month; N ¼ number; PTA ¼ balloon
angioplasty; pts ¼ patients; PTX ¼ paclitaxel; RF ¼ Rutherford; S ¼ stent; SD ¼ standard deviation; Sirol ¼ sirolimus; TLR ¼ target lesion revascularization; y ¼ years.
a Data are based on the number of limbs, and not on the number of patients.
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Finally, the quality of evidence and the results of each trial
were combined in one value to give an overview of the
ﬁndings. When outcomes between strategies were signiﬁ-
cantly different (p < .05) in favor of the intervention
strategy, the outcomes were scored as þ, þþ, or þþþ,
depending on the corresponding quality of evidence. When
a signiﬁcant difference was in favor of the comparator
strategy, the outcomes were scored as -, - -, or - - -,
depending on the corresponding quality of evidence. When
outcomes between strategies were not signiﬁcantly
different (p  .05) the outcomes were scored as ¼, ¼ ¼,
or ¼ ¼ ¼, depending on the corresponding quality of evi-
dence. When conﬂicting evidence was present, and data
could not be pooled, both qualities of evidence are depicted
in the summary of ﬁndings table.
RESULTS
Study selection
The search yielded 3658 articles, 2758 in Medline and 900
in Embase. Removal of 427 duplicates resulted in 3231 ar-
ticles to be assessed for eligibility based on title and ab-
stract. This resulted in exclusion of 3167 articles. For 64
articles, full-text had to be assessed before deciding
whether they were eligible for this systematic review.
Thirty-four articles were excluded, as 21 were only abstracts
for conference meetings, 12 were RCTs of below-the-knee
intervention, and one was a protocol publication. Finally,
30 articles5e34 were included in this review. Fig. 1 is a ﬂow
diagram of the selection process.Study characteristics
Patients. The 30 included articles were publications of 23
clinical trials of 3314 patients in total. In these trials, 15 (20
publications,5e24 2156 patients) compared BS with PTA, one
(2 publications,25,26 474 patients) DES with PTA, four (4
publications,27e30 320 patients) DEB with PTA, and four (6
publications,25,26,31e34 354 patients) DES with BS. Overall,
for all studies reporting prevalence of IC and CLI, patients
had IC in 85% and CLI in 15% of patients. For all trials, the
mean age ranged between 64 and 73 years, patients were
male in 66%, had diabetes in 37%, and were smokers in
58%. The mean lesion length per RCT ranged between 15
and 182 mm (median 68 mm). Full study characteristics of
each RCT are shown in Table 1.
Comparisons. One trial25,26 ﬁrst randomized patients to
DES or PTA, and when bailout stenting was indicated for the
PTA group, patients were randomized to bailout DES or
bailout stent. All DEB trials and the DES versus PTA trial
used paclitaxel eluting balloons or stents, whereas for the
DES versus BS trials heparin, sirolimus, or paclitaxel was
used.
Outcomes. Follow-up of patients varied from 1 to 36
months. The primary end point reported for RCTs was 6-
month or 1-year primary patency, binary restenosis, TLR,
or late lumen loss. One trial25,26 comparing DES with PTA,reported a semi-clinical outcome, that is 1-year event-free
survival as a primary end point. No study had a clinical
outcome as a primary end point.
Methodological quality and risk of bias
For most trials allocation concealment and sequence gen-
eration were performed adequately or were not sufﬁciently
reported. One of the trials19 had a high risk of bias for
sequence generation, as randomization was based on pa-
tient identiﬁcation number. No trial checked all risk factors
for baseline differences, so therefore many were scored as
unclear risk of bias for baseline characteristics. Nine trials6e
10,14,16,19,22,25,26,29 (39%) had differences in baseline char-
acteristics, and were therefore subject to a high risk of bias.
Blinding during intervention was not possible for trials
comparing BS or DES with PTA, resulting into 20 (87%)
studies6e30 scored as a high risk of bias. For item blinding
during outcome assessment, incomplete outcome data, and
selective outcome reporting, the majority of trials were
scored as adequate or unclear. Fourteen (61%) RCTs5,9,10,14e
18,20e22,24e27,31,33,34 scored high on ‘other risk of bias’, as
more than 20% of patients dropped out for outcome
assessment (11 RCTs), patients crossed over between arms
(1 RCT), outcomes reported did not match between tables
and text (1 RCT), or bailout stenting was not performed
while over 30% stenosis remained present after PTA (1
RCT). Methodological quality per RCT is shown in Fig. 2, and
overall methodological quality of RCTs per risk of bias item
is shown in Fig. 3.
Summary of ﬁndings per comparison
The summary of ﬁndings for each comparison is depicted in
Table 2. The outcomes extracted from every trial are shown
Appendix 2 (online supplementary material). An overview
of the quality of evidence per outcome is shown in
Appendix 3 (online supplementary material). The summary
ﬁndings per comparison are described below.
BS versus PTA. For most outcomes, results were available
from several follow-up stages. For the outcomes walking
capacity evaluated by questionnaire, Rutherford change,
TLR, bypass, amputation, death, and MACE, the strategies of
BS and PTA did not show signiﬁcant differences at several
time points.
For the outcomes treadmill walking capacity and binary
restenosis, results were conﬂicting, showing overall an
equal effect between BS and PTA, but also beneﬁcial effect
for both strategies at several follow-up stages. Fig. 4 shows
a meta-analyses and forest plots of 12-month TLR, binary
restenosis, and death.
DES versus PTA. Few data were available at different
follow-up stages for all outcomes. For the outcomes TLR,
patency, and EFS, low-quality evidence was available,
showing a beneﬁcial effect of a paclitaxel-DES over PTA. For
the outcomes walking capacity evaluated by questionnaire,
Rutherford improvement or change, amputation, and
death, low-quality evidence was available, showing equal
effect between both strategies.
*Figure 2.Methodological quality and risk of bias for each individual
RCT. The items were scored as adequate (þ), unclear (?), or
inadequate (-). The ﬁgure is divided into four parts, from top to
bottom, respectively, BS versus PTA, DES versus PTA, DEB versus
Figure 3. Methodological quality per item.
530 S. Jens et al.DEB versus PTA. For quality of life and walking capacity,
no results were available. For other outcomes, results on
multiple follow-up moments were available. Low- to
moderate-quality of evidence showed a positive effect of
paclitaxel-DEB compared with PTA for the outcome TLR,
with a RR of 0.20 (95% CI: 0.10 to 0.42) at 6 months and
0.27 (95% CI: 0.16 to 0.47) at 24 months after meta-
analysis. No differences between strategies were found
for the outcomes Rutherford improvement or change, ste-
nosis grade, amputation, and death at several follow-up
stages. Fig. 5 shows a meta-analyses and forest plots of 6-
month TLR and binary restenosis.
DES versus stent. Limited data were available at different
follow-up time points for all outcomes, except for reste-
nosis. For the outcomes reported on, DES performed
equally compared to BS. For binary restenosis or patency
most RCTs showed equal performance of strategies, and a
minority of studies showed a lower restenosis rate after 12
months follow-up for the DES strategy.DISCUSSION
Summary of evidence
The population evaluated had IC in 85% and CLI 15%.
Overall, quality of evidence was low to moderate. The 15
trials comparing BS with PTA (with optional bailout
stenting) showed, in general, that clinical outcomes did
not differ between both interventions after 6 to 36
months follow-up. Only for treadmill walking capacity did
BS show some beneﬁcial effect over PTA. Little evidence is
available comparing paclitaxel DES with PTA, and out-
comes such as quality of life and walking capacity have
not been studied. For ATK lesions, heparin-, sirolimus-, or
paclitaxel-DES showed no consistent beneﬁcial effect over
the use of BS. The use of paclitaxel-DEB showed no sig-
niﬁcant differences compared with PTA for change in
Rutherford classiﬁcation. However, TLR rate was signiﬁ-
cantly lower until 24 months follow-up for the DEB
strategy.PTA, and DES versus BS. * The studies of Dake et al. compared
multiple strategies, that is DES versus PTA and DES versus BS.
Table 2. Summary of ﬁndings per comparison.
BS vs PTA 1 mo 3 mo 6 mo 9 mo 12 mo 24 mo 36 mo
QoL questionnaire ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼
Treadmill walking
capacity
þþþ þþþ/- - ¼ ¼
Questionnaire walking
capacity
¼ ¼ ¼ ¼ ¼ ¼
RF change ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼
TLR ¼ ¼ ¼ ¼ (MA) ¼ ¼ ¼
Bypass ¼ ¼ (MA)
Binary restenosis ¼ ¼ ¼ (MA) þþþ (MA)/
¼ ¼ ¼
¼ ¼ ¼ ¼ (MA)/
þþþ
þþ/¼ ¼/- - -
Late lumen loss
Stenosis grade
Minor amputation ¼ ¼ (MA) ¼ ¼ ¼ ¼ ¼ ¼ (MA) ¼ ¼
Major amputation ¼ ¼ (MA) ¼ ¼ ¼ ¼ ¼ (MA) ¼ ¼
Total amputation ¼ ¼ (MA) ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ (MA) ¼ ¼
Death ¼ ¼ (MA) ¼ ¼ ¼ (MA) ¼ ¼ ¼ ¼ (MA) ¼ ¼ ¼
MACE free ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼
EFS ¼ ¼ ¼
DES vs PTA 1 mo 3 mo 6 mo 9 mo 12 mo 24 mo 36 mo
QoL questionnaire
Treadmill walking
capacity
Questionnaire walking
capacity
¼
RF change ¼
TLR þþ
Bypass
Binary restenosis þþ
Late lumen loss
Stenosis grade
Minor amputation ¼ ¼
Major amputation ¼ ¼
Total amputation ¼ ¼
Death ¼ ¼ ¼ ¼
MACE free
EFS þþ þþ
DEB vs PTA 1 mo 3 mo 6 mo 9 mo 12 mo 18e24 mo 36 mo
QoL questionnaire
Treadmill walking
capacity
Questionnaire walking
capacity
RF change þ/¼ ¼ ¼ ¼ ¼
TLR þþþ (MA) þþþ þþ (MA)
Bypass þþ
Binary restenosis þþþ (MA) ¼
Late lumen loss þþþ (MA)
Stenosis grade ¼ ¼ ¼
Minor amputation ¼ ¼ ¼ ¼
Major amputation ¼ ¼ ¼ (MA) ¼ ¼ ¼
Total amputation ¼ ¼ ¼ ¼
Death ¼ ¼ ¼ (MA) ¼ ¼ ¼
MACE free þþ
EFS
DES vs BS 1 mo 3 mo 6 mo 9 mo 12 mo 24 mo 36 mo
QoL questionnaire
Treadmill walking
capacity
Continued
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Table 2-continued
DES vs BS 1 mo 3 mo 6 mo 9 mo 12 mo 24 mo 36 mo
Questionnaire walking
capacity
¼
RF change ¼
TLR ¼ ¼
Bypass ¼ ¼ ¼ ¼
Binary restenosis ¼ ¼ ¼ þþ/¼ ¼ ¼
Late lumen loss ¼ ¼
Stenosis grade ¼ ¼
Minor amputation ¼ ¼
Major amputation ¼ ¼
Total amputation ¼ ¼
Death ¼ ¼ ¼ ¼
MACE free
EFS
þ, þþ, or þþþ refers to, respectively, very low-, low-, or moderate-quality evidence for a signiﬁcant difference (p < .05) in favor of the
intervention strategy. -, - -, or - - - refers to, respectively, very low-, low-, or moderate-quality evidence for a signiﬁcant difference (p < .05)
in favor of the comparator strategy (e.g. PTA). ¼, ¼ ¼, or ¼ ¼ ¼ refers to, respectively, very low-, low-, or moderate-quality evidence for
non-signiﬁcant difference (p  .05) between strategies. When conﬂicting evidence was present in trials, and data could not be pooled,
both qualities of evidence were depicted.BS ¼ bare stent; DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent; EFS ¼ event-free
survival; MA ¼ meta-analysis; MACE ¼ major adverse cardiac event; mo ¼ month; PTA ¼ balloon angioplasty; QoL ¼ quality of life;
RF ¼ Rutherford; TLR ¼ target lesion revascularization.
Saxon
Schillinger
Krankenberg
Chalmers
Rastan
Krankenberg
Chalmers
Brancaccio
Dick
Schillinger
Krankenberg
Chalmers
Zdanowski
Becquemin
BS versus PTA
12 mo binary restenosis
12 mo TLR
12 mo death
BS PTA
Favours BS Favours PTA
BS PTA
BS PTA
Favours BS Favours PTA
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to
to
to
to
to
to
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to
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Figure 4. Forest plots of 12-month target lesion revascularization (TLR), binary restenosis, and death, of bare stent (BS) versus balloon
angioplasty (PTA).
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DEB versus PTA
6 mo binary restenosis
6 mo TLR
DEB PTA
DEB PTA
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Figure 5. Forest plots of 6-month target lesion revascularization (TLR) and binary restenosis of drug-eluting balloon (DEB) balloon an-
gioplasty (PTA).
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Endovascular revascularization strategies using primary BS,
DES, or DEB do not evidently perform better than PTA with
optional bailout stenting in terms of clinical outcomes.
Therefore, endovascular treatment of ATK lesions in pa-
tients with IC should initially be performed using PTA,
especially as PTA is much less expensive compared with the
other treatment strategies.15 When PTA does not result into
less than 30% residual stenosis, or ﬂow-limiting dissection
occurs, bailout stenting may be performed. Stenting using
DES is not preferred, as this review did not show a signiﬁ-
cant clinical beneﬁt over the use of the less expensive BS.
For patients with CLI, no substantial evidence with regard to
clinical end points is available to recommend a speciﬁc
endovascular treatment strategy in ATK lesions other than
PTA with optional bailout stenting.Limitations of this study
The recommendation given in this review is a general
recommendation. As a result of the heterogenity between
studies, a recommendation for a speciﬁc subgroup of pa-
tients cannot be given. For instance, studies differed in
terms of lesion length, that is range of mean lesion length
was 15 to 120 mm, the number of occlusions, and post-
interventional antiplatelet protocols. Also the speciﬁc type
of stents used differed between studies and patient popu-
lation consisted of both IC and CLI patients in many trials.
Therefore, for selected groups other strategies may be
preferred, but should be studied ﬁrst.
This systematic review encountered several ﬂaws in the
design of trials. First of all, data on the more important
outcomes in the clinician’s point of view for patients with
IC, such as quality of life, walking capacity, and change in
Rutherford classiﬁcation, were reported in a minority of
studies. Other clinical data such as amputation and deathwere reported in many studies, but these outcomes are
only relevant for patients with CLI, being the minority of
patients in most trials. Therefore, clinically relevant out-
comes should be studied separately for patients with IC and
CLI. Second, most trials were industry sponsored. In this
review 13 trials were industry sponsored, ﬁve were inves-
tigator initiated, and ﬁve did not report whether they were
sponsored. This may potentially result in bias, as a recent
systematic review showed that industry sponsored studies
more often have favorable efﬁcacy results compared with
studies that were sponsored by other sources.36 Further-
more, many trials concerning new devices select a primary
outcome which might show statistically signiﬁcant differ-
ences more easily than clinical outcomes. Also clinical trials
with clinical follow-up are more expensive, and therefore
more difﬁcult to get funded. Proof of clinical efﬁcacy is in
Europe not a prerequisite for CE mark registration, as is the
case with new drugs. Therefore, most trials chose patency
or late lumen loss as their primary end point, because such
outcomes are easy to measure. Moreover, sample sizes
were relatively small, as power calculations are based on
these outcomes. As a result, studies were underpowered to
be able to determine differences in clinically more relevant
outcomes. To address this issue, we downgraded the quality
of evidence when imprecision was present.
Third, several trials considered bailout stenting as a fail-
ure in patients allocated to PTA, and did not provide data
with or without bailout stenting. We chose not to include
these studies in our systematic review, as we consider
bailout stenting to be part of the PTA strategy. As a result,
potentially relevant data of these RCTs could not be used.
Another issue considering bailout stenting was that the
choice for placing a bailout stent was not always clearly
deﬁned or just not followed. For instance, in one study16 it
was stated that bailout stenting had to be performed when
more than 30% residual stenosis remained after PTA.
534 S. Jens et al.However, although this was the case in 14 lesions, only four
were treated with a bailout stent.
Future trials should include more homogeneous study
populations, that is either patients with IC or CLI, and make
a proper assessment as to the relevant clinical outcomes for
the study population, for example wound healing for pa-
tients with CLI. Furthermore, power analyses should be
based on the relevant clinical outcomes, bailout stenting
should not be recorded as a failure, and a consistent anti-
platelet protocol should be applied.
For interpreting the reliability of systematic reviews and
meta-analysis, publication bias should be assessed, as it
has been shown that only 63% of abstracts of RCTs pre-
sented at scientiﬁc meetings are published in full within 2
years.37 Also, studies with ‘positive’ results are more
frequently published than those without ‘positive’ re-
sults.37 However, we could not study publication bias
properly, as a single funnel plot could not be constructed
because of the heterogeneity between studies in terms of
outcome reporting and follow-up time. To address this
shortcoming, the quality of evidence was downgraded one
level for every outcome.
The results of this systematic review are only relevant for
ATK arterial lesions. However, treating patients with IC or
CLI should include the entire arterial tree, as a retrospective
study showed that only 8% of the patients with IC or CLI
had a single arterial lesion at the ATK level, whereas 92%
also had one or multiple arterial lesions at the aortoiliac
level or below the knee.35CONCLUSION
In general, a low level of evidence suggests that per-
forming PTA with optional bailout stenting for ATK lesions
is the preferred endovascular strategy in patients with IC.
For selected subgroups of IC, in terms of selected patient
and lesion characteristics, optimal treatment strategies
should be further studied. For patients with CLI more
studies are needed, with a focus on quality of life, func-
tional status, and limb salvage, for recommending the
optimal treatment strategy. In future RCTs, clinical out-
comes relevant to the patient population should be the
primary end point.CONFLICT OF INTEREST
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